Sparsentan could also be a brand new treatment option for focal segmental glomerulosclerosis

Focal segmental glomerulosclerosis (FSGS) is a rare kidney disorder that affects children and adults, and might result in kidney failure. Latest findings from a team led by the University of Minnesota Medical School show patients with FSGS who were treated with the medication sparsentan experienced improved kidney function-; making it a possible recent treatment option for the disorder.

The research, published today within the Latest England Journal of Medicine, suggests sparsentan may provide kidney protection by significantly reducing excess protein in urine -; generally known as proteinuria, a proven indicator of kidney damage.

FSGS is a frustrating disease for youngsters to cope with and affects their quality of life. We’re committed to offering our patients with kidney disease access to recent treatments through our clinical trial options.”

Michelle Rheault, MD, professor on the U of M Medical School and pediatric nephrologist with M Health Fairview

Clinically, reduction of proteinuria and delaying time to kidney failure are critically essential for patients. FSGS patients on this study who were treated with sparsentan through two years of treatment had lower protein of their urine and were more prone to achieve complete remission in comparison with patients treated with irbesartan, the present standard treatment.

Although the endpoint for glomerular filtration rate-; which measures how well kidneys filter blood-; was not achieved after two years of treatment, other improvements were seen, including:

• Significant proteinuria reduction
• Higher rates of partial or complete remission
• Lower rates of reaching end-stage kidney disease

These findings suggest sparsentan could possibly be a possible recent treatment option for FSGS. Clinically, reduction of proteinuria and delaying time to kidney failure are critically essential for patients.

Further evaluation is ongoing to find out which patients with FSGS may profit essentially the most from sparsentan.

This research was funded by Travere Therapeutics-; the maker of sparsentan.